Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CGP 53353 (DAPH-7) is a PKC inhibitor with inhibitory effects on PKCβII and PKCβI and can be used to study atherosclerosis.
説明 | CGP 53353 (DAPH-7) is a PKC inhibitor with inhibitory effects on PKCβII and PKCβI and can be used to study atherosclerosis. |
ターゲット&IC50 | PKCβII:0.41 mM, PKCβI:3.8 mM |
In vitro |
In A10 cells, CGP-53353 (DAPH-7) inhibits glucose-induced cell proliferation when administered at 1 μM for 48-96 hours[1]. At a concentration of 1 μM for the initial 0-48 hours, CGP-53353 inhibits the glucose-induced increase and acceleration of DNA synthesis in A10 cells. It also blocks the glucose-induced increase in the percentage of S-phase cells[1]. |
別名 | DAPH-7 |
分子量 | 365.33 |
分子式 | C20H13F2N3O2 |
CAS No. | 145915-60-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: < 7.31 mg/mL
DMSO: 50 mg/mL (136.86 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CGP 53353 145915-60-2 Chromatin/Epigenetic Cytoskeletal Signaling PKC CGP-53353 DAPH-7 CGP53353 Inhibitor inhibitor inhibit